

## **Ablative Radiotherapy (SABR) as primary treatment in inoperable and elderly women with breast**

De Haro Piedra R\*\*1, Velázquez Miranda S\*\*\*1, Rodríguez García E\*\*1, Muñoz Carmona DM\*\*1

\*\*Servicio de Oncología Radioterápica Hospital Universitario Virgen del Rocío, Sevilla, España

\*\*\*Servicio de Física Médica Hospital Universitario Virgen del Rocío, Sevilla.

1 GiaCaMama Grupo de Investigación Avanzada en Cáncer de Mama. (EC Fase II PI 0113 16 Consejería de Salud)

**ESTRO 2023 Poster (May 2023)**

### **<Objectives>**

Our research team hypothesizes SABR (Stereotactic Ablative Body Radiotherapy) as a safe and effective primary treatment alternative to surgery in patients with inoperable breast carcinoma or who refuse surgery. It has a real impact on primary tumor control with a lower rate of local and distant recurrence

### **<Material/Methods>**

In patients older than 50 years, diagnosed by biopsy, inoperable or who failed surgery.

We used a **breast stereotactic prototype** with ribs dampening (developed and patented in our hospital and co-developed with the company **AnatGe** (figure 1).

A **MOLDCARE BR 3 (ALCARE Co., Ltd)** fixes the arms, armpits, neck and head (figure 2 a).

### **<Results>**

From June 2017 to June 2022, treatment with SABR was performed to 37 patients.

Regarding the response, 73% of the treated patients are in complete response (27 patients), 10.8% in partial response (4 patients), 10.8% (4 patients) with stable disease and only 5.4% in progression (2 patients) (figure 3).

### **<Conclusions>**

**SABR (Stereotactic Ablative Body Radiotherapy) treatment of the breast using MOLDCARE has proven to be a safe, effective treatment, with excellent local control, with minimal acute and chronic toxicity, and excellent cosmesis that it can be a radical treatment alternative to surgery in patients with breast cancer.**

Please refer to the original document as attached.